Multiple Myeloma Coverage from Every Angle

Recent News

Trends in Myeloma by Age: Treatment and Outcome Disparities Explored
ARROW Trial: Once- or Twice-Weekly Carfilzomib Plus Dexamethasone in Myeloma
Ixazomib Plus Lenalidomide/Dexamethasone for Transplant-Ineligible Patients With Myeloma
ASTRO 2020: Low-Dose Radiotherapy for Painful Osseous Lesions in Patients With Myeloma
ASTRO 2020: U.S. Trends in Use of Palliative Radiotherapy for Myeloma
Novel Peptide-Drug Conjugate Plus Dexamethasone Under Study in Resistant Myeloma
Pegfilgrastim Versus Filgrastim for Heavily Pretreated Patients With Multiple Myeloma
Adding Daratumumab to Carfilzomib-Based Therapy in Resistant Myeloma: CANDOR Trial
Post-Hoc Analysis of Belantamab Mafodotin in Resistant Myeloma From DREAMM-2
Salvage Therapy Under Study for Resistant Myeloma With Extramedullary Disease
SOHO 2020: Cross-Study Comparison of Carfilzomib, Dexamethasone, and Daratumumab Dosing Regimens in Myeloma
Triplet Regimens Compared in Newly Diagnosed Multiple Myeloma: ENDURANCE Trial
Older Adults With Myeloma: Second Primary Malignancy and Lenalidomide Therapy
Do Diagnostic Pathways Determine Multiple Myeloma Severity?
SOHO 2020: Fixed-Volume Isatuximab in Resistant Multiple Myeloma
Chromosome 1q Abnormalities in Patients With Myeloma: Predictive of Inferior Outcomes?
Transplant-Ineligible Myeloma: Comparing Regimens With and Without Daratumumab
Multiple Myeloma and COVID-19: Treatment Lessons Learned
FDA Brief: Priority Review for Melphalan Flufenamide Combination in Myeloma
Invasive Fungal Infections and Early Mortality in Patients With Multiple Myeloma
Bortezomib-Based Regimens Compared for Myeloma-Related Acute Kidney Injury
Daratumumab Combination Approved by FDA in Resistant Multiple Myeloma
Transplantation for Myeloma: Outcomes for Patients With Clonal Hematopoiesis
Differential Risks for Multiple Myeloma in New York City Neighborhoods
COVID-19 and Myeloma: Continuity of Care in Italian Tertiary Hospital
DREAMM-4 Trial Update of Belantamab Mafodotin in Myeloma
FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma
Ongoing Phase III Trial Compares Venetoclax With Standard Therapy for Resistant Myeloma
Vaccinating Against Pneumonia in Patients With Myeloma
AACR COVID-19: Older Patients With Multiple Myeloma at Risk
Subgroup Analysis of Isatuximab-Based Therapy for Resistant Myeloma
AACR COVID-19: Psychosocial Distress Among Patients With Active Myeloma
FDA Advisory Panel Votes in Favor of Approving Belantamab Mafodotin in Myeloma
FDA Accepts Supplemental New Drug Application for Selinexor in Myeloma
EHA25 Virtual: Adding Elotuzumab to Treatment Regimen in Newly Diagnosed Myeloma
FDA New Drug Application Submitted for Triple-Refractory Myeloma Combination Therapy
EHA25 Virtual: Deauville Score Criteria and Minimal Residual Disease in Myeloma
Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
EHA25 Virtual: Adding Isatuximab to Front-Line Standard of Care in High-Risk Myeloma
BELLINI Trial of Venetoclax-Based Combination Therapy in Resistant Myeloma
EHA25 Virtual: Long-Term Follow-up of Early Treatment of Smoldering Multiple Myeloma
EHA25 Virtual: Maintenance Myeloma Therapy With Ixazomib and Without AutoSCT
EHA25 Virtual: Single-Agent Belantamab Mafodotin in Resistant Myeloma
ASCO20: Update on BCMA-Directed CAR-T Cell Therapy for Resistant Myeloma
EHA25 Virtual: Adding Isatuximab to Carfilzomib and Dexamethasone in Resistant Myeloma
ASCO20: Update on Orvacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
EHA25 Virtual: BELLINI Trial Update on Venetoclax-Based Regimen in Multiple Myeloma
ASCO20: Long-Term Outcomes With AutoHCT in Multiple Myeloma
ASCO20: Adding Elotuzumab to Bortezomib-Based Therapies for High-Risk Multiple Myeloma
ASCO20: Venetoclax Combination Therapy for Resistant Myeloma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.